A novel quinoline, MT477: Suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines

Investigational New Drugs

Volumn 26, Issue 3, 2008, Pages 223-232

  Jasinski, Piotr ^a,b   Welsh, Brandon ^a   Galvez, Jorge ^c   Land, David ^d   Zwolak, Pawel ^a   Ghandi, Lori ^a   Terai, Kaoru ^a   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Advanced Medisyns Inc   (United States)

Author keywords

Caspase dependent apoptosis; MT477; New drug development; Protein Kinase C; Ras MEK ERK pathway inhibition

Indexed keywords

CISPLATIN; DIMETHYL 5,6 DIHYDRO 7 METHOXY 5,5 DIMETHYL 6 [2 (2,5 DIOXOPYRROLIDIN 1 YL)ACETYL] 1H 1 (4,5 DIMETHOXYCARBONYL 1,3 DITHIOLO 2 SPIRO)THIOPYRANO[2,3 C]QUINOLINE 2,3 DICARBOXYLATE; MT 477; PROTEIN KINASE C; QUINOLINE DERIVATIVE; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE C; QUINOLINES; RAS PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42549134968     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9096-x     Document Type: Article

References (42)

1. Galvez J, Garcia-Domenech R, de Julian-Ortiz JV, Soler R (1995) Topological approach to drug design. J Chem Inf Comput Sci 35(2):272-284
2. Llompart J, Galvez J, Pal K (2006) Inventors; US Patent 20060014770
3. Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10(12):2117-2140
4. Yoshiji H, Kuriyama S, Ways DK et al (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59(17):4413-4418
5. Hans CP, Weisenburger DD, Greiner TC et al (2005) Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Path 18(10):1377-1384
6. da Rocha AB, Mans DR, Regner A, Schwartsmann G (2002) Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 7(1):17-33
7. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP (2001) Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 61(4):1375-1381
8. Lahn M, Kohler G, Sundell K et al (2004) Protein kinase C alpha expression in breast and ovarian cancer. Oncology 67(1):1-10
9. Regala RP, Weems C, Jamieson L et al (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65(19):8905-8911
10. Mandil R, Ashkenazi E, Blass M et al (2001) Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 61(11):4612-4619
11. Liu JF, Crepin M, Liu JM, Barritault D, Ledoux D (2002) FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 293(4):1174-1182
12. Villalonga P, Lopez-Alcala C, Chiloeches A et al (2002) Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts. J Biol Chem 277(40):37929-37935
13. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP (2004) Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 279(21):22118-22123
14. Dudek AZ, Zwolak P, Jasinski P et al (2007) Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs, Sep 6.
15. Slupsky JR, Kamiguti AS, Harris RJ, Cawley JC, Zuzel M (2007) Central role of protein kinase Cepsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia. Am J Pathol 170(2):745-754
16. Song MS, Park YK, Lee JH, Park K (2001) Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. Cancer Res 61(22):8322-8330
17. Kolch W, Heidecker G, Kochs G et al (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364(6434):249-252
18. Goode N, Hughes K, Woodgett JR, Parker PJ (1992) Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 267(24):16878-16882
19. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev 3(1):11-22
20. Johnson L, Mercer K, Greenbaum D et al (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410(6832):1111-1116
21. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ (2000) Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10(4):147-154
22. Downward J (2006) Signal transduction. Prelude to an anniversary for the RAS oncogene. Science 314(5798):433-434
23. D'Argenio D (1997) Adapt II User's Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software. Los Angeles: Biomedical Simulations Resource
24. Okudela K, Hayashi H, Ito T et al (2004) K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol 164(1):91-100
25. Toulany M, Dittmann K, Kruger M, Baumann M, Rodemann HP (2005) Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 76(2):143-150
26. Gorczyca W, Bigman K, Mittelman A et al (1993) Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 7(5):659-670
27. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z (1993) The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 53(13):3186-3192
28. Wyllie AH, Kerr JF, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68:251-306
29. Scholz C, Wieder T, Starck L et al (2005) Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 24(11):1904-1913
30. Qiu RG, Chen J, Kirn D, McCormick F, Symons M (1995) An essential role for Rac in Ras transformation. Nature 374(6521):457-459
31. Clark JA, Black AR, Leontieva OV et al (2004) Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. J Biol Chem 279(10):9233-9247
32. Basu A, Tu H (2005) Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta. Biochem Biophys Res Commun 334(4):1068-1073
33. Muscella A, Greco S, Elia MG, Storelli C, Marsigliante S (2004) Differential signalling of purinoceptors in HeLa cells through the extracellular signal-regulated kinase and protein kinase C pathways. J Cell Physiol 200(3):428-439
34. Weisstein JS, Majeska RJ, Klein MJ, Einhorn TA (2001) Detection of c-fos expression in benign and malignant musculoskeletal lesions. J Orthop Res 19(3):339-345
35. Wang ZQ, Grigoriadis AE, Mohle-Steinlein U, Wagner EF (1991) A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras. EMBO J 10(9):2437-2450
36. Zajchowski DA, Bartholdi MF, Gong Y et al (2001) Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61(13):5168-5178
37. Kustikova O, Kramerov D, Grigorian M et al (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18(12):7095-7105
38. Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139
39. Chen Z, Gibson TB, Robinson F et al (2001) MAP kinases. Chem Rev 101(8):2449-2476
40. Celano P, Berchtold CM, Mabry M et al (1993) Induction of markers of normal differentiation in human colon carcinoma cells by the v-rasH oncogene. Cell Growth Differ 4(4):341-347
41. Wang X, Studzinski GP (2001) Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem 80(4):471-482
42. Cheng M, Zhen E, Robinson MJ, Ebert D, Goldsmith E, Cobb MH (1996) Characterization of a protein kinase that phosphorylates serine 189 of the mitogen-activated protein kinase homolog ERK3. J Biol Chem 271(20):12057-12062